ArticleInflammatory bowel diseases2026

Prospective real-world experience with risankizumab in difficult-to-treat Crohn's disease: results from the Dutch Initiative on Crohn and Colitis Registry.

Loriane M M Verleye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.